Tandem Diabetes Care (NASDAQ:TNDM) Upgraded to Outperform at Leerink Partnrs

Leerink Partnrs upgraded shares of Tandem Diabetes Care (NASDAQ:TNDM) from a market perform rating to an outperform rating in a research report report published on Thursday morning, Zacks.com reports.

Several other research firms also recently weighed in on TNDM. Stifel Nicolaus boosted their target price on Tandem Diabetes Care from $37.00 to $40.00 and gave the company a buy rating in a research report on Tuesday. Citigroup upped their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the company a neutral rating in a research report on Wednesday, April 3rd. StockNews.com raised Tandem Diabetes Care from a sell rating to a hold rating in a research report on Friday, April 19th. Finally, SVB Leerink raised Tandem Diabetes Care from a market perform rating to an outperform rating and upped their price objective for the company from $34.00 to $45.00 in a research report on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of Moderate Buy and an average target price of $39.45.

Tandem Diabetes Care Stock Performance

NASDAQ TNDM opened at $35.56 on Thursday. The company has a market cap of $2.30 billion, a P/E ratio of -10.34 and a beta of 1.12. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. The business’s 50 day moving average price is $30.74 and its 200-day moving average price is $25.26. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $40.74.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. Sell-side analysts predict that Tandem Diabetes Care will post -1.62 earnings per share for the current year.

Institutional Investors Weigh In On Tandem Diabetes Care

Several hedge funds have recently made changes to their positions in TNDM. RiverPark Advisors LLC purchased a new stake in shares of Tandem Diabetes Care in the 4th quarter worth $27,000. MCF Advisors LLC lifted its holdings in shares of Tandem Diabetes Care by 79.3% in the 1st quarter. MCF Advisors LLC now owns 1,006 shares of the medical device company’s stock worth $36,000 after buying an additional 445 shares during the period. Signaturefd LLC lifted its holdings in shares of Tandem Diabetes Care by 871.8% in the 4th quarter. Signaturefd LLC now owns 1,691 shares of the medical device company’s stock worth $50,000 after buying an additional 1,517 shares during the period. Arcadia Investment Management Corp MI lifted its holdings in shares of Tandem Diabetes Care by 141.6% in the 1st quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock worth $66,000 after buying an additional 1,085 shares during the period. Finally, PNC Financial Services Group Inc. lifted its holdings in shares of Tandem Diabetes Care by 51.7% in the 3rd quarter. PNC Financial Services Group Inc. now owns 3,226 shares of the medical device company’s stock worth $67,000 after buying an additional 1,099 shares during the period.

Tandem Diabetes Care Company Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.